ahjay, First I want to say that I wasn't intending to be rude or...

ahjay,

First I want to say that I wasn't intending to be rude or personal in my last post.

It's just that being a biotech investor on a number of exchanges, I see much higher valuations and very early deals being done on the AIM, DAX and in the US.

Bristol Myers paid a massive $1.85b upfront for 35% of Nektar's drug.

Compared with some of the deals we are seeing on the world stage, imu are not way too early imho. And imu's platform is playing on a world stage. Personally I would describe them as "ripe" for a deal at this time, but that's just my opinion of course.

But lets see what transpires.

cheers